Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial.
Alderuccio JP, Alencar AJ, Schatz JH, Kuker RA, Pongas G, Reis IM, Lekakis LJ, Spiegel JY, Sandoval-Sus J, Beitinjaneh A, Stanchina MD, Trabolsi A, Lossos IS, Rosenblatt JD, Lessen DS, Moskowitz CH. Alderuccio JP, et al. Lancet Haematol. 2025 Jan;12(1):e23-e34. doi: 10.1016/S2352-3026(24)00345-4. Epub 2024 Dec 7. Lancet Haematol. 2025. PMID: 39662486 Clinical Trial.
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia.
Stanchina MD, Montoya S, Danilov AV, Castillo JJ, Alencar AJ, Chavez JC, Cheah CY, Chiattone C, Wang Y, Thompson M, Ghia P, Taylor J, Alderuccio JP. Stanchina MD, et al. Among authors: alderuccio jp. Nat Rev Clin Oncol. 2024 Dec;21(12):867-887. doi: 10.1038/s41571-024-00956-1. Epub 2024 Nov 1. Nat Rev Clin Oncol. 2024. PMID: 39487228 Review.
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.
Bommier C, Link BK, Gysbers BJ, Maurer MJ, Larson MC, Khurana A, Wang Y, Thompson CA, Chihara D, Alderuccio JP, Koff JL, Epperla N, Conconi A, Lossos IS, Nowakowski GS, Feldman AL, Habermann TM, King RL, Cerhan JR. Bommier C, et al. Among authors: alderuccio jp. Blood Adv. 2024 Dec 10;8(23):5939-5948. doi: 10.1182/bloodadvances.2024013188. Blood Adv. 2024. PMID: 39321424 Free PMC article.
Transformation of marginal zone lymphoma to Hodgkin lymphoma.
Moalem KN, Alderuccio JP, Bommier C, Habermann T, Link BK, Cerhan JR, Florindez J, Lossos IS. Moalem KN, et al. Among authors: alderuccio jp. Blood Adv. 2024 Sep 10;8(17):4559-4562. doi: 10.1182/bloodadvances.2024013434. Blood Adv. 2024. PMID: 39024508 Free PMC article. No abstract available.
Not all central nervous system lymphomas are created equal.
Alencar AJ, Alderuccio JP. Alencar AJ, et al. Among authors: alderuccio jp. Haematologica. 2024 Sep 1;109(9):2769-2771. doi: 10.3324/haematol.2024.285388. Haematologica. 2024. PMID: 38634145 Free PMC article. No abstract available.
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.
Arcaini L, Bommier C, Alderuccio JP, Merli M, Fabbri N, Nizzoli ME, Maurer MJ, Tarantino V, Ferrero S, Rattotti S, Talami A, Murru R, Khurana A, Mwangi R, Deodato M, Cencini E, Re F, Visco C, Feldman AL, Link BK, Delamain MT, Spina M, Annibali O, Pulsoni A, Ferreri AJM, Stelitano CC, Pennese E, Habermann TM, Marcheselli L, Han S, Reis IM, Paulli M, Lossos IS, Cerhan JR, Luminari S. Arcaini L, et al. Among authors: alderuccio jp. EClinicalMedicine. 2024 Apr 11;72:102592. doi: 10.1016/j.eclinm.2024.102592. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38633575 Free PMC article.
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR. Cerhan JR, et al. Among authors: alderuccio jp. Am J Hematol. 2024 Mar;99(3):408-421. doi: 10.1002/ajh.27202. Epub 2024 Jan 13. Am J Hematol. 2024. PMID: 38217361
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.
Hamadani M, Spira A, Zhou X, Liao L, Chen L, Radford J, Ai W, Solh M, Ardeshna KM, Hess B, Caimi PF, Stathis A, Carlo-Stella C, Alderuccio JP, Kahl B, Wang Y, Qin Y, Xu ZC, Zinzani PL. Hamadani M, et al. Among authors: alderuccio jp. Blood Adv. 2024 Jan 9;8(1):93-98. doi: 10.1182/bloodadvances.2023010636. Blood Adv. 2024. PMID: 37871303 Free PMC article. No abstract available.
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
Alderuccio JP, Reis IM, Hamadani M, Nachiappan M, Leslom S, Kahl BS, Ai WZ, Radford J, Solh M, Ardeshna KM, Hess BT, Lunning MA, Zinzani PL, Stathis A, Carlo-Stella C, Lossos IS, Caimi PF, Han S, Yang F, Kuker RA, Moskowitz CH. Alderuccio JP, et al. Clin Cancer Res. 2024 Jan 5;30(1):139-149. doi: 10.1158/1078-0432.CCR-23-1561. Clin Cancer Res. 2024. PMID: 37855688 Free PMC article.
66 results